[{"from": "human", "value": "Provide a description of this molecule. [C][C][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][N][C][=C][Branch1][#Branch1][C][=C][N][=C][Ring1][=Branch1][C][=C][N][=C][Branch1][#Branch1][N][=C][Ring1][=Branch1][Ring1][=N][N][C][=N][C][=C][Branch1][#C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][=Branch1][C][=O][C][O][C][=C][Ring1][=C]"}, {"from": "gpt", "value": "The molecule is an organic heterotricyclic compound that is 9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine which is substituted by a [6-(hydroxyacetyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]nitrilo group at position 2 and by a trans-4-methylcyclohexyl group at position 9. It is a FLT3 and CDK4 dual kinase inhibitor that has antineoplastic activity. Currently under clinical investigation in patients with relapsed or refractory acute myeloid leukemia (AML). It has a role as an antineoplastic agent, an apoptosis inducer, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is a secondary amino compound, a tertiary amino compound, a naphthyridine derivative, a primary alpha-hydroxy ketone and an organic heterotricyclic compound."}]